All In Biotech

Drug Trial Radar · NCT07465718

Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

38

Planned (sponsor's estimate)

Start

Sep 3, 2026

Primary completion

Feb 2028

Study completion Feb 2028

Sponsor

Lead sponsor
OrphalanIndustry
Sponsor type
Industry
First posted
Mar 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 8 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if a new trientine tetrahydrochloride (TETA 4HCl) formulation administered once a day compared to d-Penicillamine (DPA) as a first line treatment for people living with Wilson's disease (WD) is effective and safe. The study is enrolling children aged 8 years and older weighing at least 55 lb (25 kg) and adults with a recent diagnosis of WD. People recently diagnosed with WD, may be eligible for the study if they have either not started copper chelating treatment (such as DPA or trientine) or have been taking zinc salts for less than 28 days. Participants will be randomly allocated (like tossing a coin) to receive either DPA or TETA 4HCL for 48 weeks. During this time period participants will have up to 12 visits for health checks and assessments including blood and urine testing. In addition, at some visits participants may be asked to complete questionnaires on treatment satisfaction, and overall well-being.

Conditions

  • Wilson's Disease

Interventions

  • TETA 4HCl formulationDrug

    The new formulation of TETA 4HCl will be administered once a day. Each film-coated tablet is scored to enable halving, if required. Randomized participants are planned to receive TETA 4HCl for the 48-week post-randomization period.

  • D-PenicillamineDrug

    Standard of care DPA is to be used, per the sites and treating physician's usual practice. To be administered in accordance with the product labelling and/or the institutions treatment practice guidelines. Randomised participants are planned to receive DPA for the 48-week post-randomization period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute value of serum NCC at Week 48 assessed using the NCC-speciation assay (serum NCC-Sp)Time frame: Week 48

Locations

10 sites in 4 countries. Site status is shown where the registry gives one.

  • University of Colorado Anschutz School of Medicine

    Denver, Colorado · Recruiting

  • Yale University School of Medicine

    New Haven, Connecticut · Not yet recruiting

  • University of Michigan Medical Centre

    Ann Arbor, Michigan · Recruiting

  • Beijing YouAn Hospital, Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Friendship Hospital,Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, Zhengjiang Province, China · Recruiting

  • PIMS Hospital

    Islamabad, Pakistan · Not yet recruiting

  • Shifa International Hospital

    Islamabad, Pakistan · Not yet recruiting

  • Children's Hospital & Institute of Child Health

    Lahore, Pakistan · Not yet recruiting

  • King Faisal Specialist Hospital and Research Center

    Riyadh, Saudi Arabia · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.